Document Detail


Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
MedLine Citation:
PMID:  22644797     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: To evaluate the effect of food on axitinib pharmacokinetics in healthy volunteers with two different crystal polymorphs. METHODS: Two separate open-label, randomized, single-dose, three-period, crossover trials were conducted. Study I, conducted first using 5-mg axitinib Form IV film-coated immediate-release (FCIR) tablets, enrolled 18 subjects to compare fed versus fasted states and 24 subjects to evaluate the effect of timing of food consumption on axitinib pharmacokinetics. Study II enrolled 30 subjects to assess the effect of food using 5-mg axitinib Form XLI FCIR tablets. Subjects received axitinib after overnight fasting, with limited fasting or, depending on the study design, after consuming high-fat, high-calorie or moderate-fat, standard-calorie meals. RESULTS: For Form IV FCIR, compared with overnight fasting, axitinib plasma exposure [area under the concentration curve (AUC)] was decreased 23 % when administered with food. For Form XLI FCIR, mean axitinib plasma AUC and maximum plasma concentration (C (max)) were 19 and 11 % higher, respectively, with a high-fat, high-calorie meal compared with overnight fasting. When Form XLI FCIR was administered with moderate-fat, standard-calorie meal, AUC and C (max) were 10 and 16 % lower compared with overnight fasting. Both formulations were well tolerated. Adverse events, mostly gastrointestinal (7 % with Form IV FCIR and 13 % with Form XLI FCIR), were mild to moderate in both studies. CONCLUSIONS: While axitinib Form IV FCIR was associated with higher plasma exposure after overnight fasting, axitinib Form XLI FCIR can be administered with or without food as differences in axitinib pharmacokinetics under the two conditions were not clinically meaningful.
Authors:
Yazdi K Pithavala; Ying Chen; Melvin Toh; Paulina Selaru; Robert R Labadie; May Garrett; Brian Hee; Janessa Mount; Grace Ni; Karen J Klamerus; Michael A Tortorici
Related Documents :
9877537 - Trace elements in formulas based on cow and soy milk and in austrian cow milk determine...
12613807 - Titanium(iv) tungstosilicate and titanium(iv) tungstophosphate: two new inorganic ion e...
19159157 - "solving xor": correction to grand and honey (2008).
19834257 - Individual susceptibility to cadmium toxicity and metallothionein gene polymorphisms: w...
18979587 - Ferrous gluconate and ferrous sulfate added to a complementary food distributed by the ...
17192477 - Role for mitochondrial reactive oxygen species in brain lipid sensing: redox regulation...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-27
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  -     ISSN:  1432-0843     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Clinical Pharmacology, Oncology Business Unit, Pfizer Inc., 10555 Science Center Drive, San Diego, CA, 92121, USA, yazdi.pithavala@pfizer.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Next Document:  Farletuzumab, an anti-folate receptor ? antibody, does not block binding of folate or anti-folates t...